Maruho Co. Ltd.
Latest From Maruho Co. Ltd.
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Asia Deal Watch: Antibody-Drug Conjugates Reign With Alliances Involving Celltrion, Miracogen & WuXi Biologics
Celltrion and iProgen will co-develop ADC candidates, Miracogen and Synaffix sign a technology license after a successful research collaboration, and WuXi will provide clinical trial material to NBE Therapeutics.
Galderma’s novel biologic is heading for Phase III studies in moderate-to-severe atopic dermatitis as the race to join Dupixent in an expanding market hots up.
- Topical Delivery
- Drug Delivery
- Therapeutic Areas
- Pacific Rim
- Parent & Subsidiaries
- Maruho Co. Ltd.
- Senior Management
Koichi Takagi, Pres. & CEO
Yasuhiko Kito, Exec. Corp. Officer, R&D & Quality Assurance
Atsushi Sugita, Exec. Corp. Officer, Bus. Operations, Admin.
Yasuyuki Ishimaru, Corp. Officer, Sales
Yutaka Ishihama , Corp. Officer, Dev.
Yuji Hanaoka, Corp. Officer, Bus. Dev. & Licensing
- Contact Info
Maruho Co. Ltd.
Phone: (81) 63 718 876
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.